Cargando…

Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity

The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world’s population at record speeds. However, there is still a demand for alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Scaglione, Antonella, Opp, Silvana, Hurtado, Alicia, Lin, Ziyan, Pampeno, Christine, Noval, Maria G., Thannickal, Sara A., Stapleford, Kenneth A., Meruelo, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359677/
https://www.ncbi.nlm.nih.gov/pubmed/34394127
http://dx.doi.org/10.3389/fimmu.2021.719077
_version_ 1783737592986992640
author Scaglione, Antonella
Opp, Silvana
Hurtado, Alicia
Lin, Ziyan
Pampeno, Christine
Noval, Maria G.
Thannickal, Sara A.
Stapleford, Kenneth A.
Meruelo, Daniel
author_facet Scaglione, Antonella
Opp, Silvana
Hurtado, Alicia
Lin, Ziyan
Pampeno, Christine
Noval, Maria G.
Thannickal, Sara A.
Stapleford, Kenneth A.
Meruelo, Daniel
author_sort Scaglione, Antonella
collection PubMed
description The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world’s population at record speeds. However, there is still a demand for alternative effective vaccines that rapidly confer long-term protection and rely upon cost-effective, easily scaled-up manufacturing. Here, we present a Sindbis alphavirus vector (SV), transiently expressing the SARS-CoV-2 spike protein (SV.Spike), combined with the OX40 immunostimulatory antibody (αOX40) as a novel, highly effective vaccine approach. We show that SV.Spike plus αOX40 elicits long-lasting neutralizing antibodies and a vigorous T-cell response in mice. Protein binding, immunohistochemical, and cellular infection assays all show that vaccinated mice sera inhibits spike functions. Immunophenotyping, RNA Seq transcriptome profiles, and metabolic analysis indicate a reprogramming of T cells in vaccinated mice. Activated T cells were found to mobilize to lung tissue. Most importantly, SV.Spike plus αOX40 provided robust immune protection against infection with authentic coronavirus in transgenic mice expressing the human ACE2 receptor (hACE2-Tg). Finally, our immunization strategy induced strong effector memory response, potentiating protective immunity against re-exposure to SARS-CoV-2 spike protein. Our results show the potential of a new Sindbis virus-based vaccine platform to counteract waning immune response, which can be used as a new candidate to combat SARS-CoV-2. Given the T-cell responses elicited, our vaccine is likely to be effective against variants that are proving challenging, as well as serve as a platform to develop a broader spectrum pancoronavirus vaccine. Similarly, the vaccine approach is likely to be applicable to other pathogens.
format Online
Article
Text
id pubmed-8359677
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83596772021-08-13 Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity Scaglione, Antonella Opp, Silvana Hurtado, Alicia Lin, Ziyan Pampeno, Christine Noval, Maria G. Thannickal, Sara A. Stapleford, Kenneth A. Meruelo, Daniel Front Immunol Immunology The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world’s population at record speeds. However, there is still a demand for alternative effective vaccines that rapidly confer long-term protection and rely upon cost-effective, easily scaled-up manufacturing. Here, we present a Sindbis alphavirus vector (SV), transiently expressing the SARS-CoV-2 spike protein (SV.Spike), combined with the OX40 immunostimulatory antibody (αOX40) as a novel, highly effective vaccine approach. We show that SV.Spike plus αOX40 elicits long-lasting neutralizing antibodies and a vigorous T-cell response in mice. Protein binding, immunohistochemical, and cellular infection assays all show that vaccinated mice sera inhibits spike functions. Immunophenotyping, RNA Seq transcriptome profiles, and metabolic analysis indicate a reprogramming of T cells in vaccinated mice. Activated T cells were found to mobilize to lung tissue. Most importantly, SV.Spike plus αOX40 provided robust immune protection against infection with authentic coronavirus in transgenic mice expressing the human ACE2 receptor (hACE2-Tg). Finally, our immunization strategy induced strong effector memory response, potentiating protective immunity against re-exposure to SARS-CoV-2 spike protein. Our results show the potential of a new Sindbis virus-based vaccine platform to counteract waning immune response, which can be used as a new candidate to combat SARS-CoV-2. Given the T-cell responses elicited, our vaccine is likely to be effective against variants that are proving challenging, as well as serve as a platform to develop a broader spectrum pancoronavirus vaccine. Similarly, the vaccine approach is likely to be applicable to other pathogens. Frontiers Media S.A. 2021-07-29 /pmc/articles/PMC8359677/ /pubmed/34394127 http://dx.doi.org/10.3389/fimmu.2021.719077 Text en Copyright © 2021 Scaglione, Opp, Hurtado, Lin, Pampeno, Noval, Thannickal, Stapleford and Meruelo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Scaglione, Antonella
Opp, Silvana
Hurtado, Alicia
Lin, Ziyan
Pampeno, Christine
Noval, Maria G.
Thannickal, Sara A.
Stapleford, Kenneth A.
Meruelo, Daniel
Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
title Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
title_full Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
title_fullStr Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
title_full_unstemmed Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
title_short Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
title_sort combination of a sindbis-sars-cov-2 spike vaccine and αox40 antibody elicits protective immunity against sars-cov-2 induced disease and potentiates long-term sars-cov-2-specific humoral and t-cell immunity
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359677/
https://www.ncbi.nlm.nih.gov/pubmed/34394127
http://dx.doi.org/10.3389/fimmu.2021.719077
work_keys_str_mv AT scaglioneantonella combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT oppsilvana combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT hurtadoalicia combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT linziyan combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT pampenochristine combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT novalmariag combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT thannickalsaraa combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT staplefordkennetha combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT meruelodaniel combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity